Alphabet Inc (NASDAQ:GOOGL) Verily and GlaxoSmithKline plc (ADR) (NYSE:GSK)has struck a deal last week to establish Galvani Bioelectronics.
The pharmaceutical giant will own 55% of the new bioelectronics company, bringing to the table its years of pharmaceutical experience as well as its disease expertise. Meanwhile, Verily, owning the remaining 45% of Galvani Bioelectronics, will combine with GlaxoSmithKline’s prowess its miniaturization technology, data analytics expertise, and device and software development capabilities.
Both Verily and GlaxoSmithKline are collaborating over $700 million in intellectual property (IP) rights under the new partnership.
Kris Famm, GlaxoSmithKline Vice President (VP) of Bioelectronics Research and Development (R&D), will serve as Galvani Electronics President. The global R&D center of GlaxoSmithKline in the UK will house the main headquarters of Galvani Bioelectronics. At South San Francisco, Verily will also house a Galvani Bioelectronics facility.
Brian Otis, Verily Chief Technology Officer (CTO) noted that the powerhouse partnership between Verily and GlaxoSmithKline can ignite the potentials of an emerging bioelectronics industry. Otis reiterated that the successful thrive in the said field requires the powerful combination of miniaturization and biology expertises, which is highly evident in the newly-formed alliance.
Moreover, Otis elaborated that Galvani Bioelectronics will be, as much as possible, a standalone company to enable it to focus more on its prospects. While it will receive the full support of its parent companies, Otis believes that Galvani Bioelectronics needs to function on its own to attain the best possible long-term results.
GlaxoSmithKline’s Bioelectronics Initiatives
GlaxoSmithKline has been pushing into bioelectronics for four years now, aiming to use miniaturized, implantable bioelectronic devices in treating chronic illnesses. Basically, the implants are capable of reversing disease states. Part of these efforts is the development of what GlaxoSmithKline dubs, “nerve atlas”, a mapped outline of how all the nerves in the human body are linked to all the organs and diseases.
The company upholds that bioelectronics can pave way for new advancements in treating arthritis, asthma, diabetes, among others. GlaxoSmithKline has initiated in 2013 a venture fund worth $50 million for its bioelectronics developments, underscoring its commitment in the emerging field.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...